Literature DB >> 21757333

Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome.

Elena-Ioana Braicu1, Jalid Sehouli, Rolf Richter, Klaus Pietzner, Werner Lichtenegger, Christina Fotopoulou.   

Abstract

OBJECTIVE: Recurrence rates of Epithelial Ovarian Cancer (EOC) remain high. Aim of the present study was to compare tumour pattern and surgical outcome at primary and secondary tumourdebulking in a paired patients' collective.
METHODS: Seventy-nine consecutive EOC-patients who underwent both primary and secondary cytoreduction in our institution between 09/2000 and 12/2010 were evaluated according to a validated documentation-tool ('IMO', Intraoperative Mapping Ovarian Cancer). Differences in tumour-pattern between paired samples were examined using McNemar-test or sign-test.
RESULTS: A complete macroscopic tumour resection could be achieved significantly more often during primary versus secondary surgery (77% versus 50%; p<0.001) in comparable operative times (242 min versus 199 min; p=0.15) and by equivalent operative morbidity (25% versus 29%; p=0.424). Tumour-residuals at primary correlated significantly with tumour-residuals at secondary cytoreduction (p=0.003). Patients at relapse had significantly higher rates of tumour involvement of the gastric serosa (2.5% versus 16.9%; p=0.001), serosa of small intestine (20.3% versus 44.9%; p<0.001) and mesentery (30.4% versus 50%; p=0.012). The relative-risk for peritoneal carcinosis, intestinal tumour involvement or positive lymph nodes at secondary tumourdebulking in the case of presence of these features at primary surgery was 1.53 (95% CI: 0.89-2.63); 0.92 (95% CI: 0.65-1.31) and 1.49 (95% CI: 0.83-2.68), respectively, and thus not reaching a statistical significance.
CONCLUSIONS: Secondary cytoreduction due to EOC appears to be associated with significantly lower optimal tumourdebulking rates compared to primary setting, since the disease tends to recur in patterns less accessible to complete resection such as gastrointestinal serosa, mesentery and upper abdomen. By maximal surgical effort, tumour residuals significantly correlate between primary and secondary cytoreduction. No other predictors of surgical outcome or tumour-pattern could be identified.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21757333     DOI: 10.1016/j.ejca.2011.06.034

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Standardizing surgical treatment in malignant pleural mesothelioma.

Authors:  David Rice
Journal:  Ann Cardiothorac Surg       Date:  2012-11

2.  Correlation of Pattern of Spread and Outcomes in Advanced Epithelial Ovarian Cancers.

Authors:  Amrutha Ramachandran; Anupama Rajanbabu; Kiran Gulabrao Bagul; Keechilat Pavithran; Dehannathparambil K Vijaykumar
Journal:  Indian J Surg Oncol       Date:  2017-02-02

3.  The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Ovarian Cancer.

Authors:  Wan Kyu Eo; Hye Jung Chang; Sang Hoon Kwon; Suk Bong Koh; Young Ok Kim; Yong Il Ji; Hong-Bae Kim; Ji Young Lee; Dong Soo Suh; Ki Hyung Kim; Ik Jin Chang; Heung Yeol Kim; Suk Choo Chang
Journal:  J Cancer       Date:  2016-01-29       Impact factor: 4.207

Review 4.  The role of surgery in advanced epithelial ovarian cancer.

Authors:  María Martín-Cameán; Elsa Delgado-Sánchez; Antonio Piñera; Maria Dolores Diestro; Javier De Santiago; Ignacio Zapardiel
Journal:  Ecancermedicalscience       Date:  2016-08-17

5.  Preoperative Monocyte-to-Lymphocyte Ratio in Peripheral Blood Predicts Stages, Metastasis, and Histological Grades in Patients with Ovarian Cancer.

Authors:  Jiangdong Xiang; Lina Zhou; Xing Li; Wei Bao; Taizhong Chen; Xiaowei Xi; Yinyan He; Xiaoping Wan
Journal:  Transl Oncol       Date:  2016-11-24       Impact factor: 4.243

6.  Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial.

Authors:  Radoslav Chekerov; Philipp Harter; Stefan Fuxius; Lars Christian Hanker; Linn Woelber; Lothar Müller; Peter Klare; Wolfgang Abenhardt; Yoana Nedkova; Isil Yalcinkaya; Georg Heinrich; Harald Sommer; Sven Mahner; Pauline Wimberger; Dominique Koensgen-Mustea; Rolf Richter; Gülten Oskay-Oezcelik; Jalid Sehouli
Journal:  Gynecol Oncol Res Pract       Date:  2017-03-07

7.  Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer.

Authors:  Paula Cunnea; Sally Gowers; James E Moore; Emmanuel Drakakis; Martyn Boutelle; Christina Fotopoulou
Journal:  Converg Sci Phys Oncol       Date:  2017-02-23

8.  Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?

Authors:  C Fotopoulou; K Savvatis; P Kosian; I E Braicu; G Papanikolaou; K Pietzner; S-C Schmidt; J Sehouli
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

9.  Small Bowel PCI Score as a Prognostic Factor of Ovarian Cancer Patients Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), a Retrospective Analysis of 130 Patients.

Authors:  Christos Iavazzo; Alexandros Fotiou; Victoria Psomiadou; Sofia Lekka; Dimitrios Katsanos; John Spiliotis
Journal:  Indian J Surg Oncol       Date:  2021-03-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.